R744 + R744

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia in Pre-Dialysis Patients

Conditions

Anemia in Pre-Dialysis Patients

Trial Timeline

Feb 1, 2007 → Nov 1, 2008

About R744 + R744

R744 + R744 is a phase 3 stage product being developed by Chugai Pharmaceutical for Anemia in Pre-Dialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00433615. Target conditions include Anemia in Pre-Dialysis Patients.

What happened to similar drugs?

20 of 20 similar drugs in Anemia in Pre-Dialysis Patients were approved

Approved (20) Terminated (5) Active (0)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00433849Phase 3Completed
NCT00433615Phase 3Completed
NCT00433888Phase 3Completed

Competing Products

20 competing products in Anemia in Pre-Dialysis Patients

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
LY2787106Eli LillyPhase 1
29
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
PrasugrelDaiichi SankyoPhase 1
29
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40